Magid and Co

Magid and Co focuses on providing data and analysis related to Series A and Series B funding activities worldwide (excluding China), targeting non-therapeutics sectors with a raised amount over $5M. It includes deal trends, investor behaviors, and insights for founders navigating the early-stage funding market.

Early-stage funding Series A and B investment trends Global startup ecosystem excluding China Investment strategies for startups Non-therapeutics sectors funding Investor and founder advice Market dynamics and deal volumes

The hottest Substack posts of Magid and Co

And their main takeaways
39 implied HN points 08 Feb 24
  1. Series B deal volume increased significantly in January compared to December, which is positive news for founders seeking funding.
  2. Data focused on Series B deals globally (excluding China) with amounts raised over $5M and companies not centered on therapeutics.
  3. The post provides insights into recent Series B activity, highlighting key statistics and trends in the sector.
19 implied HN points 22 Jan 24
  1. In the last week, there were only 15 Series A deals with funding amounts ranging from $5.5M to $55M.
  2. The focus was on Series A deals worldwide (excluding China), where the raised amount was over $5M and not in therapeutics.
  3. Readers can subscribe for free to receive new posts and support the author's work on Magid and Co.
39 implied HN points 11 Oct 23
  1. Series B deals show a trend of shrinking, with few exceptions like a $1.6B raised by a steel company.
  2. In September 2023, nine rounds in various sectors, from AI to defense, exceeded $100M.
  3. Data on Series B deals worldwide (excluding China) above $5M is provided, excluding therapeutics-focused companies.
Get a weekly roundup of the best Substack posts, by hacker news affinity:
59 implied HN points 08 Aug 23
  1. Data on Series B deals done in July 2023 is available for download in PDF format
  2. The summary stats include data on Series B deals done worldwide (ex-China) with an amount raised greater than $5M, excluding companies focused on therapeutics
  3. Readers are encouraged to forward the information to anyone planning to raise an A or B round in the next six months
39 implied HN points 05 Sep 23
  1. Series B deals over $100M declined over the years - from 15 deals in 2021 to none in 2023.
  2. Series B deal volumes decreased significantly in two years, indicating a shift in deal trends.
  3. Data on Series B deals worldwide (ex-China) shows deals with a raised amount above $5M and non-therapeutics companies.
39 implied HN points 28 Aug 23
  1. The post discusses Series A deals from the week of August 21, 2023, providing data on global deals over $5M not in the therapeutics sector.
  2. The summary stats focus on Series A deals worldwide (excluding China) with fundraising exceeding $5M and companies not concentrated on therapeutics.
  3. Readers can subscribe for free to stay updated on posts and support the author's work at Magid and Co.
39 implied HN points 21 Aug 23
  1. The post shares data on Series A deals done in the last week.
  2. The data focuses on worldwide Series A deals excluding China, with an amount raised greater than $5M and companies not focused on therapeutics.
  3. Readers are encouraged to subscribe to receive new posts and support the author's work.
19 implied HN points 08 Nov 23
  1. The post provides data on Series B deals done in October 2023
  2. The data focuses on Series B deals worldwide (excluding China) that raised more than $5M and were not in the therapeutics sector
  3. The post offers a summary of statistics for Series B deals
39 implied HN points 24 Jul 23
  1. The post shares data on Series A deals done in the last week of July 2023.
  2. The summary stats provide information on Series A deals worldwide, excluding China, where the amount raised is over $5M, and the company is not focused on therapeutics.
  3. The post encourages readers to subscribe for free to receive new posts and support the author's work.
19 implied HN points 16 Oct 23
  1. The post shares data about Series A deals completed in the last week.
  2. The summary statistics focus on Series A deals globally (excluding China) with fundraising exceeding $5M and companies not in therapeutics.
  3. Readers are encouraged to subscribe for free to receive more posts and show support.
39 implied HN points 05 Jul 23
  1. There was a significant decrease in Series A deal activity from June 2022 to June 2023, with 290 deals in 2022 compared to 146 in 2023.
  2. It's crucial for founders to closely monitor individual firm actions rather than just market-level statistics, especially when major players from previous years are less active.
  3. Founders seeking funding should focus on understanding which investors are actively writing checks and building relationships with these firms, even if they are less known or harder to reach.
19 implied HN points 02 Oct 23
  1. The post provides data on Series A deals done in the week of September 25, 2023
  2. The summary stats focus on Series A deals worldwide (ex-China) where the amount raised is greater than $5M and not focused on therapeutics
  3. The post encourages readers to subscribe for free to receive new posts and support the author's work
19 implied HN points 05 Sep 23
  1. A program called Shortcut Labs has been launched to help companies raise Series A funding easier by focusing on building repeatable growth for exceptional companies.
  2. The post shares data on Series A deals worldwide (excluding China) where the amount raised is over $5M and the company is not focused on therapeutics.
  3. Readers are encouraged to subscribe to Magid and Co for more updates on Series A activity and to support the work.
19 implied HN points 31 Jul 23
  1. Data on Series A deals done in the last week is available for download. The deals worldwide exclude China and focus on amounts greater than $5M.
  2. The summary stats show global Series A deals not focused on therapeutics and with amounts raised over $5M.
  3. Readers can subscribe for free to receive new posts and support the work of Magid and Co.
19 implied HN points 12 Jun 23
  1. This post provides data on Series A deals done in the last week.
  2. The information covers Series A deals worldwide (excluding China) where companies raised over $5M and are not focused on therapeutics.
  3. Readers can subscribe for free to receive new posts and support the author's work.
19 implied HN points 02 Jun 23
  1. The Series A market has a significant gap between the number of funds a founder knows and the number actually leading rounds, leading to inefficiencies.
  2. There is a challenge for founders to discover funds that could fit, and for funds to find suitable companies without appearing intrusive or shady.
  3. Fundamental changes in operational approaches are needed to address the challenges in fund discovery and cold outreach, tools alone may not be enough.
0 implied HN points 19 Jun 23
  1. The post provides data on Series A deals done in the last week of June 12, 2023.
  2. Information is available for Series A deals worldwide (excluding China) where the amount raised is above $5M and the focus is not on therapeutics.
  3. Readers can subscribe for free to receive new posts and support the work of Magid and Co.
0 implied HN points 10 Jul 23
  1. Data on Series A deals done in the last week is shared in a post.
  2. Summary stats show Series A deals done worldwide (ex-China) where the amount raised is over $5M and companies are not focused on therapeutics.
  3. Magid and Co offers free subscriptions for new posts sharing Series A activities.
0 implied HN points 26 Jun 23
  1. The post shares data on Series A deals done in the last week, focusing on the lead investors involved in the deals.
  2. There have been worldwide Series A deals (excluding China) where more than $5M was raised and the companies were not focused on therapeutics.
  3. Readers can subscribe for free to stay updated on new posts and support the author's work.
0 implied HN points 29 May 23
  1. Data on Series A deals done worldwide (ex-China) with funding over $5M is shared.
  2. Focus is on companies not centered on therapeutics in these Series A deals.
  3. Readers can subscribe to Magid and Co to receive updates and support the work.
0 implied HN points 23 May 23
  1. The post discusses Series A deals done in the week of May 15, 2023.
  2. It includes data and statistics on the Series A activities during that week.
  3. The post is from magid.substack.com and shares information about Series A deals in a specific timeframe.
0 implied HN points 05 Jun 23
  1. Series A deals data for the week of May 29, 2023 were shared, focusing on deals with amounts raised over $5M worldwide (excluding China) for companies not focused on therapeutics.
  2. Weekly Series A Ticktock 2023 PDF file of 65.8KB was made available for download, providing more in-depth information on the deals.
  3. Readers are encouraged to subscribe for free to receive new posts and to support the author's work.
0 implied HN points 27 Nov 23
  1. The post shares data on Series A deals done in the last week.
  2. The summary stats focus on Series A deals worldwide (excluding China) with raised amounts over $5M, not in therapeutics industry.
  3. Readers can subscribe for free to receive new posts and support the author's work.
0 implied HN points 05 Feb 24
  1. In the last week, the deal volume for Series A remained the same, but the amount raised in these rounds decreased by approximately 18%.
  2. The data provided focuses on Series A deals worldwide (except China) where the amount raised is over $5M, excluding companies centered on therapeutics.
  3. Readers are encouraged to subscribe to Magid and Co for more updates and to show support.
0 implied HN points 29 Jan 24
  1. Deal volume for Series A activity increased by approximately 60% compared to the previous week
  2. One notable Series A deal was Krutrim SI Designs raising $50M at a $1B post from Matrix Partners
  3. Data focused on Series A deals worldwide (excluding China) where the amount raised is over $5M and the companies are not focused on therapeutics
0 implied HN points 18 Jan 24
  1. 2023 was challenging for companies raising venture capital, with the total capital, deal volume, and median deal size being below the peak in 2021-2022.
  2. Notable trend: Later stage rounds were more affected than early stage ones, possibly due to their IPO expectations and proximity to public markets.
  3. Brand name investors reduced activity, with a drop in the number of Series A, B, and C rounds led by them compared to the broader market, suggesting founders need to pitch to a broader range of funds.
0 implied HN points 11 Dec 23
  1. The post provides data on Series A deals done in the last week
  2. The focus is on Series A deals worldwide (excluding China) where amount raised is over $5M and not on therapeutics
  3. Readers can subscribe for free to receive new posts and support the author's work
0 implied HN points 07 Dec 23
  1. In November, only 4 out of 48 Series B deals had traditional VCs as lead investors, a low ratio.
  2. Despite Thanksgiving, deal volume increased by 20% compared to October in Series B activity.
  3. Total deal value went up by approximately $100 million from $1.79 billion to $1.88 billion in November.
0 implied HN points 06 Nov 23
  1. The post shares data on Series A deals done in the last week.
  2. The focus is on Series A deals worldwide excluding China, raising more than $5M, and not focused on therapeutics.
  3. Readers are encouraged to subscribe for more updates and to support the author's work.